Loading...
•
Jun 30, 2023
Novavax Q2 2023 Earnings Report
Reported second quarter financial results and operational highlights.
Key Takeaways
Novavax reported a total revenue of $424 million and a net income of $58 million for the second quarter of 2023. The company has reduced its current liabilities and is progressing with its updated XBB COVID vaccine.
Second quarter total revenue was $424 million and net income was $58 million.
A new strategic partnering agreement with SK bioscience was executed, including an equity investment of $85 million in Novavax.
Negotiated up to $350 million in 2023 payments under the amended Canada APA.
Initiated FDA submission for approval of the updated XBB COVID vaccine for the 2023 fall vaccination season and reiterated plan to be in market by September.
Revenue by Segment
Forward Guidance
Novavax updated its Full Year 2023 Financial Guidance and expects to achieve total revenue between $1.3 billion and $1.5 billion and combined R&D and SG&A expenses between $1.3 billion and $1.4 billion.
Positive Outlook
- Full Year 2023 Total Revenue is expected to be between $1,300 million and $1,500 million.
- Grant Revenue is expected to be between $340 million and $360 million.
- Product Sales are expected to be between $960 million and $1,140 million.
- Combined R&D and SG&A expenses are expected to be between $1,300 million and $1,400 million.
- The guidance reflects APAs based on 2023 committed dose delivery schedules of approximately $700 million and U.S. market sales, subject to updated variant manufacturing and regulatory approvals.
Challenges Ahead
- Challenges satisfying various safety, efficacy, and product characterization requirements.
- Difficulty obtaining scarce raw materials and supplies.
- Resource constraints, including human capital and manufacturing capacity.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...